Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)

Haowen Tang, Wenwen Zhang, Junning Cao, Yinbiao Cao, Xinyu Bi, Haitao Zhao, Ze Zhang, Zhe Liu, Tao Wan, Ren Lang, Wenbing Sun, Shunda Du, Yongping Yang, Yinying Lu, Daobing Zeng, Jushan Wu, Binwei Duan, Dongdong Lin, Fei Li, Qinghua Meng, Jun Zhou, Baocai Xing, Xiaodong Tian, Jiye Zhu, Jie Gao, Chunyi Hao, Zhiqiang Wang, Feng Duan, Zhijun Wang, Maoqiang Wang, Bin Liang, Yongwei Chen, Yinzhe Xu, Kai Li, Chengang Li, Minggen Hu, Zhao-Hai Wang, Shouwang Cai, Wenbin Ji, Nian-Xin Xia, Wenheng Zheng, Hongguang Wang, Li Gong, Ziman Zhu, Zhiyong Huang, Wanguang Zhang, Kaishan Tao, Jun Liang, Keming Zhang, Chaoliu Dai, Jiangtao Li, Qiu Qiu, Yuan Guo, Liqun Wu, Weibao Ding, Zhenyu Zhu, Wanqing Gu, Jingyu Cao, Zusen Wang, Lantian Tian, Huiguo Ding, Guangming Li, Yongyi Zeng, Kui Wang, Ning Yang, Haosheng Jin, Yajin Chen, Yinmo Yang, Dianrong Xiu, Mao-Lin Yan, Xiaodong Wang, Quanli Han, Shunchang Jiao, Guang Tan, Jizhou Wang, Lianxin Liu, Jinghai Song, J. Y. Liao, Hong Zhao, Peng Li, Tianqiang Song, Zhanbo Wang, Jing Yuan, Bingyang Hu, Yufeng Yuan, Meng Zhang, Shuyang Sun, Jialin Zhang, Wentao Wang, Tianfu Wen, Jiayin Yang, Xilin Du, Tao Peng, X Y Feng, Zuojin Liu, Weibo Niu, Ping Liang, Jianming Xu, Xiao Zhao, Min ZhuBioScience 2024 · DOI

TL;DR

This paper presents an updated consensus from Chinese experts on using a combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic targeted drugs (AATDs) to treat advanced hepatocellular carcinoma (HCC). The goal is to "convert" unresectable tumors into resectable ones, enabling curative surgery and improving long-term survival for patients with this challenging disease.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC), the most common type of liver cancer, is often diagnosed at advanced stages when effective treatment options are limited, leading to poor prognoses. While traditional treatments like surgery or systemic therapies have limitations for advanced HCC, recent advancements in immunotherapy (ICIs) and targeted therapy (AATDs) have shown significant promise. This paper addresses the need for a standardized, expert-driven approach to integrating these novel therapies with surgical interventions, specifically focusing on "conversion therapy" – using these drugs to shrink tumors enough for surgical removal. The consensus aims to update previous guidelines and provide clear recommendations for clinical practice.

Methods

This document is not a research paper presenting novel experimental methods or datasets. Instead, it's an expert consensus statement. The "methods" involved:

  • In-depth discussions: Leading domestic experts in hepatobiliary and pancreatic diseases, liver cancer, and surgery convened.
  • Literature review: A comprehensive search of databases (PubMed, Web of Science, CNKI, Wanfang) and recent international conference abstracts was conducted.
  • Evidence-based evaluation: Recommendations were graded using the Oxford Centre for Evidence-Based Medicine Grading system (levels 1-5) and categorized as Strong (A), Moderate (B), or Weak (C) recommendations.
  • Consensus building: Opinions were discussed online, in writing, and through offline seminars, with final consensus achieved through voting (≥80% agreement).
  • Registration: The consensus was registered on the International Practice Guideline Registration for Transparency (PREPARE) Platform.

Datasets

Not applicable. This is an expert consensus document, not a research study that collects or analyzes new data.

Key Insights and Ideas

  • Conversion Therapy as a Bridge: The core idea is that ICIs + AATDs can act as a bridge, transforming unresectable tumors into surgically treatable ones, thereby offering a chance for a radical cure and improved long-term survival.
  • ICI + AATD Synergy: The combination of ICIs and AATDs is highlighted as the preferred first-line treatment for advanced HCC, offering better outcomes than monotherapy and opening doors for conversion therapy.
  • Sequential Surgery is Key: The ultimate goal of conversion therapy is to enable sequential curative surgery (hepatectomy or liver transplantation), which is crucial for achieving long-term survival benefits.
  • Standardized Evaluation is Crucial: The consensus emphasizes the importance of standardized imaging (mRECIST) and tumor marker evaluations to assess treatment response and determine the optimal timing for surgery.
  • Multidisciplinary Approach: Effective conversion therapy and subsequent management require a collaborative effort from a multidisciplinary team (MDT).
  • Managing Adverse Events: While effective, ICIs and AATDs have associated adverse reactions that need careful monitoring and management, with specific guidelines provided.

Key Results

This consensus document doesn't present quantitative results in the traditional sense. Instead, it provides a set of recommendations and guidelines based on the synthesis of existing evidence and expert opinion. Key "results" include:

  • Consensus on ICI + AATD: Strong recommendation (A) for using ICI + AATD regimens as the preferred approach for conversion therapy.
  • Surgical Criteria: Detailed technical criteria for surgical resection after conversion therapy are outlined (e.g., Child-Pugh class A/B, adequate future liver remnant, ICG <20%).
  • Evaluation Intervals: Recommendations for evaluating treatment response every three cycles (6-8 weeks) of conversion therapy, with flexibility for adjustment.
  • Tumor Marker Significance: Acknowledgment of the role of AFP and PIVKA-II in predicting response, with significant decreases suggesting effectiveness.
  • Pathological Evaluation: Emphasis on the importance of pathological examination of excised specimens for assessing treatment efficacy and guiding adjuvant therapy.
  • Adverse Event Management: Principles for managing severe adverse reactions, including dose adjustment, discontinuation, and symptomatic treatment.

Limitations and Future Work

  • Lack of Head-to-Head Trials: The authors acknowledge that high-level evidence from direct comparative randomized controlled trials for conversion therapy and sequential surgery is still lacking.
  • Need for Further Validation: While promising, the long-term survival outcomes of some combined immuno-targeted therapy and local treatment strategies still require confirmation.
  • Defining Optimal Timing: Determining the precise optimal timing for surgery after conversion therapy remains an area for further investigation.
  • Standardization Challenges: Differences in patient characteristics, definitions of conversion success, and resectability criteria across studies present challenges for direct comparisons.
  • Future Directions: The consensus implicitly points towards the need for more prospective studies, particularly randomized controlled trials, to further refine treatment strategies, optimize surgical timing, and validate the long-term benefits of this approach. The paper also highlights the ongoing development of adjuvant therapies and the importance of continued multidisciplinary collaboration.

Summary updated

Abstract

Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few years, the combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy has proven highly efficacious in treating advanced HCC, significantly extending patients' survival and providing a potential for sequential curative surgery. After sequential curative hepatectomy or liver transplantation following conversion therapy, patients can receive long-term survival benefits. In order to improve the long-term survival rate of the overall population with liver cancer and achieve the goal of a 15% increase in the overall 5-year survival rate outlined in the Healthy China 2030 blueprint, the Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Chinese Society of Liver Cancer, and the Liver Study Group of Surgery Committee of Beijing Medical Association organized in-depth discussions among relevant domestic experts in the field. These discussions focused on the latest progress since the release of the Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2021 Edition) and resulted in a new consensus on the modifications and supplements to related key points. This consensus aims to further guide clinical practice, standardize medical care, and promote the development of the discipline.
BibTeX
@inproceedings{tang2024chinese,
  author = {Haowen Tang and Wenwen Zhang and Junning Cao and Yinbiao Cao and Xinyu Bi and Haitao Zhao and Ze Zhang and Zhe Liu and Tao Wan and Ren Lang and Wenbing Sun and Shunda Du and Yongping Yang and Yinying Lu and Daobing Zeng and Jushan Wu and Binwei Duan and Dongdong Lin and Fei Li and Qinghua Meng and Jun Zhou and Baocai Xing and Xiaodong Tian and Jiye Zhu and Jie Gao and Chunyi Hao and Zhiqiang Wang and Feng Duan and Zhijun Wang and Maoqiang Wang and Bin Liang and Yongwei Chen and Yinzhe Xu and Kai Li and Chengang Li and Minggen Hu and Zhao-Hai Wang and Shouwang Cai and Wenbin Ji and Nian-Xin Xia and Wenheng Zheng and Hongguang Wang and Li Gong and Ziman Zhu and Zhiyong Huang and Wanguang Zhang and Kaishan Tao and Jun Liang and Keming Zhang and Chaoliu Dai and Jiangtao Li and Qiu Qiu and Yuan Guo and Liqun Wu and Weibao Ding and Zhenyu Zhu and Wanqing Gu and Jingyu Cao and Zusen Wang and Lantian Tian and Huiguo Ding and Guangming Li and Yongyi Zeng and Kui Wang and Ning Yang and Haosheng Jin and Yajin Chen and Yinmo Yang and Dianrong Xiu and Mao-Lin Yan and Xiaodong Wang and Quanli Han and Shunchang Jiao and Guang Tan and Jizhou Wang and Lianxin Liu and Jinghai Song and J. Y. Liao and Hong Zhao and Peng Li and Tianqiang Song and Zhanbo Wang and Jing Yuan and Bingyang Hu and Yufeng Yuan and Meng Zhang and Shuyang Sun and Jialin Zhang and Wentao Wang and Tianfu Wen and Jiayin Yang and Xilin Du and Tao Peng and X Y Feng and Zuojin Liu and Weibo Niu and Ping Liang and Jianming Xu and Xiao Zhao and Min Zhu},
  title = {{Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)}},
  booktitle = {BioScience},
  year = {2024},
  doi = {10.5582/bst.2024.01394},
}
Figure